Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma

Jens Nielsen50 enrolled

Overview

In this study, glycosaminoglycan (GAG) profiling in subjects diagnosed with metastatic renal cell carcinoma (mRCC) is hypothesized to be useful in monitoring drug response and predict radiological response. To this end, glycosaminoglycan scores based on longitudinal samples of plasma and urine in prospectively enrolled patients will be correlated to radiological response to first-line therapy based on current standard-of-care. A positive correlation indicates that glycosaminoglycan scores can successfully detect patients that are not responding to treatment before the scheduled follow-up in which radiological imaging is performed. Data on the extent of metastasis (number of metastatic sites) will be collected to assess whether glycosaminoglycans correlate accordingly.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Renal Cell

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Diagnosis of renal cell carcinoma * Metastatic disease * Predicted life expectancy over 2 months * Patient referred for first line drug therapy * Standard imaging evaluation 12 weeks prior to inclusion * Planned for standard imaging within 16 weeks after start of therapy * Informed consent Exclusion Criteria: * Lack of proper compliance to accept continuous samplings

Locations (1)

Outcomes

Primary Outcomes

Area under the receiver operating characteristic (ROC) curve (AUC) for the sensitivity/specificity of plasma/urine glycosaminoglycan scores to progressive disease at response evaluation

ROC curves are generated to determine the specificity and sensitivity of the glycosaminoglycan scores sampled at 6 weeks and every 3 months to progressive disease as assessed by radiological imaging during the scheduled response evaluation according to RECIST 1.1. criteria. The area under each ROC curve (AUC) is then calculated as primary outcome measure.

Time frame: 6 weeks and every 3 months after treatment start up to 12 months

Secondary Outcomes

Area under the receiver operating characteristic (ROC) curve (AUC) for the sensitivity/specificity of plasma/urine glycosaminoglycan scores in early prediction of objective response at first response evaluation

ROC curves are generated to determine the specificity and sensitivity of the glycosaminoglycan scores sampled at 6 weeks to complete response or partial response as assessed by radiological imaging during the first scheduled response evaluation according to RECIST 1.1. criteria. The area under each ROC curve (AUC) is then calculated as primary outcome measure.

Time frame: Baseline; 6 weeks after treatment start